Perspective · 27 May 2024
Conference abstractPublished 27 May 2022
Molecular epidemiology of Oesophageal Squamous Cell ; a Comparative Study of Kenya and South Africa
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Received Date: May 13, 2022 Accepted Date: May 20, 2022 Published Date: May 27, 2022 Oesophageal cancer ranks sixth in incidence and fifth in mortality globally with a significantly high proportion of young patients with the disease have been reported in developing countries. Kenya and South Africa have reported a high incidence and mortality due to oesophageal squamous cell carcinoma (OSCC) whose aetiology remains inconclusive and multiple factors including environmental exposures are believed to play important roles. Despite the high prevalence and mortality in Kenya, no systematic or genome-wide sequencing studies have been done on this type of tumour and very little is known about the molecular and genetic aberrations in OSCC in Kenya. The study proposes to determine the molecular epidemiology of OSCC and assess the risk factors, the common gene polymorphisms and genetic mutations in Kenyan cases. The results will be compared with South Africa OSCC published data in silico to assess their similarities if any. Kenyan OSCC biopsies shall be collected from Nairobi, Muranga and Machakos Counties and transported to JKUAT laboratory from where DNA shall be extracted from matched normal and tumour biopsies as well as blood. The processed DNA will be packaged and stored for transportation to South Africa where whole genome sequencing will be carried out. Somatic mutations will be determined in genomic DNA. The sequence data will be analysed using bioinformatics tools developed at the Cancer Genome Project. Comprehensive bioinformatics algorithms for the identification of putative genomic rearrangements will be used from massively parallel paired-end sequencing that will help in mapping of the sequence reads and pairing of the two ends using the BWA algorithm. The benefits of the study will be detection of mutation signatures. The study will also help to associate mutation signatures with carcinogen exposure in the environment and finally test the specific mutations/ exposures and outcomes in response to treatment of OSCC in collaboration with GlaxoSmithKline pharmaceutical company.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Colorectal Cancer: Open Access.
Perspective · 27 May 2024
Epigenetic Modifications in Colorectal Cancer: The Role of Wnt Signaling Inhibitors
Perspective · 25 May 2024
Influence of Tumor Location on Prognosis in Patients with Endoscopically Removed Dangerous Polyps
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalColorectal Cancer: Open Access
- SubjectGastroenterology & Hepatology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Peris Wambugu”
